{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-000614","form_type":"8-K","ticker":"ATAI","cik":"0002081043","company_name":"AtaiBeckley Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.203381+00:00","generated_at":"2026-05-16T11:16:09.694914+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AtaiBeckley provides 2026 milestones; BPL-003 Phase 3 start Q2'26, VLS-01 data H2'26","bullets":["BPL-003 (mebufotenin) Phase 2b TRD trial met primary and all key endpoints; Phase 3 guidance Q1'26, trial start Q2'26 pending FDA End-of-Phase 2 meeting.","Additional BPL-003 Phase 2a cohort evaluating two-dose induction in TRD starts Q1'26; initial data expected Q4'26.","VLS-01 (DMT buccal film) Phase 2 Elumina trial topline data from 142 TRD patients expected H2'26.","EMP-01 (oral R-MDMA) SAD Phase 2a topline data expected Q1'26; new patent provides exclusivity through 2043.","Redomiciliation to Delaware completed Dec 2025; added to NASDAQ biotech index (NBI) Dec 2025; cash runway into 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-000614","json":"https://secwatch.observer/filing/0001140361-26-000614.json","markdown":"https://secwatch.observer/filing/0001140361-26-000614.md","text":"https://secwatch.observer/filing/0001140361-26-000614.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126000614/0001140361-26-000614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126000614/ef20062505_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:16:09.694914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}